Nibec was established in January 2004 with the aim of applying academic achievements in peptide-based drug delivery systems, biomaterial technology for tissue regeneration, and peptide engineering technology to product development. The company focuses on the development and commercialization of peptide pharmaceuticals, peptide fusion biomaterials, protein engineering-based pharmaceuticals for diagnosis and treatment, biomaterials for tissue regeneration, and oral healthcare products. Based on its core peptide technology, it has completed patent registrations related to regenerative therapy in Korea, the U.S., and Europe.

PEPscovery : The bioactive peptide was identified by Peptide discovery (PEPscovery) platform technology. The biosamples such as blood or tissues from patients were collected and find selective biomarkers in biosamples using big data platform. The bioactive peptide that can interact with selective phenotypic biomarkers was identified by phage display method. The in vitro and in vivo repeated bio panning discovered highest binding phages and resultant highest affinity peptide. The isolated peptide was chemically synthesized, then efficacy and safety were tested to confirm the bioactive peptide as therapeutic candidate. PDC (Peptide Drug Conjugate) : NIBEC’s technology is based on a unique peptide-delivery carrier, NIPEP-TPP (NIBEC PEPtide as Target Penetrating Peptide). This target-selective cell-penetrating carrier consists of three sections: a cell-penetrating peptide; a linker that can be joined to a cargo drug; and a targeting moiety peptide. Consequently, NIPEP-TPPs enable the creation of peptide-drug conjugates (PDCs) that, depending on the targeting moiety, can be selectively delivered to almost any specific cell or tissue with high efficiency and safety.

Public

Biotech